Pan-cancer immune and stromal deconvolution predicts clinical outcomes and mutation profiles

Bhavneet Bhinder1,2, Verena Friedl3,4, Sunantha Sethuraman5

  • 1Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY, 10021, USA.

Scientific Reports
|July 4, 2025
PubMed

Insights

This study comprehensively analyzes the tumor microenvironment (TME) across 33 cancer types, revealing unique cellular portraits. Leukocytes are key in differentiating tumors, and an immune-rich TME predicts better survival in specific bladder cancer and melanoma subtypes.

Area of Science:

  • Oncology
  • Immunology
  • Bioinformatics

Background:

  • Traditional gene expression deconvolution methods analyze limited cell types, failing to capture the tumor microenvironment's (TME) full complexity.
  • A comprehensive understanding of TME cellular composition is crucial for cancer research and therapeutic development.

Purpose of the Study:

  • To integrate multiple deconvolution tools for a comprehensive assessment of TME cellularity across diverse cancer types.
  • To identify distinct TME patterns and their correlation with clinical outcomes and mutational profiles.

Main Methods:

  • Integration of nine deconvolution tools to analyze 79 TME cell types.
  • Analysis of 10,592 tumor samples from 33 distinct cancer types.
  • Correlation analysis between TME profiles, survival data, and mutational status.

Main Results:

  • Identification of 41 distinct immune infiltration and stroma profiles, revealing unique TME portraits for each cancer type.
  • Leukocytes were found to be major drivers in distinguishing tumor types.
  • A shared immune-rich TME cluster was associated with improved survival in specific subtypes of bladder cancer and melanoma.

Conclusions:

  • This integrated approach provides the most comprehensive analysis of the TME to date.
  • Leukocyte infiltration patterns are critical for tumor classification and prognosis.
  • The study identified 35 potential biomarkers for therapeutic targeting and predicting treatment response, including CASP8 and RAS pathway genes.